The FDA has dashed Sanofi's hopes of launching its type I diabetes drug, Zynquista, this year. News FDA rejects oral Type I diabetes drug The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).
FarmaKology Newsletter - Issue #1
FarmaKology Newsletter - Issue #1
FarmaKology Newsletter - Issue #1
The FDA has dashed Sanofi's hopes of launching its type I diabetes drug, Zynquista, this year. News FDA rejects oral Type I diabetes drug The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).